nasopharyngeal cancer

nasopharyngeal cancer

a malignant neoplastic disease of the nasopharynx. Depending on the site of a nasopharyngeal tumor, there may be nasal obstruction, otitis media, hearing loss, sensory or motor nerve damage, bony destruction of the skull, or deep cervical lymphadenopathy. Diagnostic measures include nasopharyngoscopy, biopsy, and radiological examination of the skull with tomographic studies. Squamous cell and undifferentiated carcinomas are the most common lesions. Nasopharyngeal cancer occurs rarely in the United States and frequently in southern China. Exposure to dusts of nickel, chromium, wood, and leather and to isopropyl oil increases the risk of developing nasopharyngeal cancer. High titers of antibodies to the Epstein-Barr virus are found in Chinese patients with the cancer, and there is evidence of genetic susceptibility, because a certain histocompatibility antigen is associated with the disease and multiple cases occur in some families. Radiation is the most effective therapy, and chemotherapy is also used.

nasopharyngeal carcinoma

A rare (in the West) malignancy which is endemic in regions of southern China—where it comprises up to 18% of cancers—as well as in southeast Asia. It is linked to EBV infection, diets high in nitrosamines and inhaled carcinogens. It is more common in males and has a peak incidence of age 40 to 50.

DiffDx
Lymphoma (DLCBL, Hodgkin's), reactive lymphoid proliferation, sarcomas.

Management
Radiotherapy, chemotherapy.

Prognosis
Stage dependant; 5-year survival is 55%.

Nasopharyngeal carcinomas (WHO, 2005)
- Keratinising squamous cell carcinoma
- Non keratinsing carcinoma
  • Differentiated
  • Undifferentiated
- Basaloid squamous cell carcinoma
- Nasopharyngeal cancer, staging
  • Stage I—Lesion confined to nasopharynx.
  • Stage II
    A) Lesion extends to oropharynx and/or nasal fossa.
    B) Lesion extends to nearby lymph nodes or to parapharyngeal region.
  • Stage III—Lesion spread to lymph nodes on both sides of the neck or nearby bones or sinuses.
  • Stage IV
    A) Spread beyond nasopharynx to other areas in head; possible spread to regional lymph nodes.
    B) Spread beyond nasopharynx to other areas in head and to lymph nodes above clavicle, or are ≥ 6 cm in greatest dimension.
    C) Metastasised.

nasopharyngeal carcinoma

Nasopharyngeal cancer A rare malignancy, which is endemic to regions of southern China and Southeast Asia; persons with serologic markers for EBV–IgA antibodies against EBV capsid antigen and/or neutralizing antibodies against EBV-specific DNase have a 3-fold cumulative risk of nasopharyngeal cancer if one marker was positive and a 35-fold risk if both markers are positive. See Epstein-Barr virus.
Nasopharyngeal cancer
Stage I Lesion confined to nasopharynx
Stage II
A  Lesion extends to oropharynx and/or nasal fossa
B  Lesion extends to nearby lymph nodes or to parapharyngeal region
Stage III Lesion spread to lymph nodes on both sides of the neck or to nearby bones or sinuses
Stage IV
A Spread beyond nasopharynx to other areas in head, and  possibly to nearby lymph nodes
B Spread beyond nasopharynx to other areas in head and to lymph nodes above clavicle or are ≥ 6 cm
C Lesion has metastasized
References in periodicals archive ?
Bile duct tumors, bladder cancer, brain tumors, breast cancer, cervical cancer, colon cancer, colorectal cancer, esophageal cancer, gastric cancer, glioblastoma, head & neck cancer, hepatocellular carcinoma, leukemia's, lung cancer, lymphoma's, melanoma, mesothelioma, multiple myeloma, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, sarcoma, thyroid cancer
Clinicopathologic features, treatment, and prognosis of postirradiation osteosarcoma in patients with nasopharyngeal cancer.
The low rates of nasopharyngeal cancer prevalent in the industry, which are elevated over those found in the surrounding communities and nationally, are averages.
Three objective and ongoing responses have been observed in the first 9 evaluable patients who received at least 2 doses, including one patient each with nasopharyngeal cancer (partial response), gastrointestinal stromal tumor (GIST) (minor response), and uterine cancer (minor response).
g, angiofibromas), nasopharyngeal cancer, and foreign-body impaction.
Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.
Patterns of failure in nasopharyngeal cancer treated with megavoltage irradiation.
Not only am I alive today because of proton therapy, but I can see," said Susan Heuer of Chicago who was treated for nasopharyngeal cancer earlier this year at the Proton Therapy Center of Massachusetts General Hospital in Boston.
In addition to the significant association between tonsillar and nasopharyngeal cancer and HPV, our analysis of descriptive variables confirmed the association between the incidence of these neoplasms and poor oral hygiene and low socioeconomic status in older adults.
Seliciclib in nasopharyngeal cancer (Phase 2 randomized study in progress)
Seliciclib has been evaluated to date in approximately 380 patients and is currently being evaluated in a randomized Phase 2 trial in patients with previously treated nasopharyngeal cancer.
Phase 2 trial of seliciclib in patients with nasopharyngeal cancer (NPC)